Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin as Monotherapy in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
Conditions
Interventions
Sotagliflozin (SAR439954)
Placebo
Locations
70
United States
Investigational Site Number 8401049
Tucson, Arizona, United States
Investigational Site Number 8401026
Tucson, Arizona, United States
Investigational Site Number 8401028
Anaheim, California, United States
Investigational Site Number 8401057
Canoga Park, California, United States
Investigational Site Number 8401058
Garden Grove, California, United States
Investigational Site Number 8401029
Hawaiian Gardens, California, United States
Start Date
November 11, 2016
Primary Completion Date
April 22, 2019
Completion Date
May 17, 2019
Last Updated
June 21, 2021
NCT07232537
NCT06278207
NCT07051005
NCT06887049
NCT04943861
NCT07433062
Lead Sponsor
Lexicon Pharmaceuticals
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions